ASX News

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

Telix today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (Merck), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019.

TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. Under the terms of the collaboration, and based on encouraging pre-clinical data derived from the initial strategic research collaboration, the two parties have agreed to investigate the synergy of these investigational assets with Merck’s DDRi compound across a wide variety of oncology indications in the clinic.

Telix CEO, Dr. Christian Behrenbruch said, “This collaboration represents the vanguard of nuclear medicine and oncology, and we are excited by the level of new data and intellectual property already generated, which is highly supportive of clinical translation. Pre-clinical studies provide evidence that the combined effect of Merck’s DDRi compound with Telix’s MTR candidates has potential to significantly impact cancer by improving efficacy and reducing the required radiation dose for tumour reduction and remission, compared to MTR only.”

To read the full ASX disclosure please click here.

To return to the Telix homepage please click here.

More Articles

Corporate Spotlight

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...

Corporate Spotlight

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...

ASX News

NCCN Guidelines Updated to Include PSMA-PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...

ASX News

FDA Approves Phase II Kidney Cancer Therapy Study

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...

ASX News

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...

ASX News

Japanese Prostate Cancer Imaging Study Completes Enrolment

Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...

ASX News

Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...

ASX News

Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...

ASX News

Telix Half-Year Results 2021 and Company Update Conference Call

Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update

ASX News

Telix Expands Prostate Cancer Activity with GenesisCare Collaboration

Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...

ASX News

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

ASX News

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...

ASX News

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...

ASX News

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...

ASX News

Telix H1 2021 Results and Company Update Conference Call

Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...

ASX News

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...

Corporate Spotlight

Ms. Helen Hovenga Joins Telix as Chief People Officer

4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...

ASX News

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...

ASX News

Activities Report and Appendix 4C for June 2021 Quarter

Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...

ASX News

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...

Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...

Corporate Spotlight

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...

ASX News

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...

ASX News

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...